ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Neon Therapeutics Inc

Neon Therapeutics Inc (NTGN)

3.07
0.00
(0.00%)
Closed March 29 04:00PM
0.00
0.00
(0.00%)

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
3.07
Bid
3.00
Ask
3.46
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
3.07
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

NTGN Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

NTGN Discussion

View Posts
ClayTrader ClayTrader 4 years ago
* * $NTGN Video Chart 04-22-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
Rsarabjit Rsarabjit 4 years ago
Neon Therapeutics News: NTGN Stock Rockets 38% on BioNTech Deal

BioNTech is acquiring Neon Therapeutics

By William White, InvestorPlace Writer Jan 16, 2020, 4:06 pm EST

Neon Therapeutics (NASDAQ:NTGN) news for Thursday about a deal with BioNTech (NASDAQ:BNTX) has NTGN stock soaring on Thursday.

?

Source: Shutterstock.com

A Neon Therapeutics news releasereveals that BioNTech is going to be acquiring the company. This will have it purchasing all shares of NTGN stock in a deal valued at roughly $67.00 million.
The deal will have Neon Therapeutics merging with Endor Lights, which is a wholly-owned subsidiary of BioNTech. Investors in NTGN stock will receive 0.063 shares of BNTX stock in exchange for each NTGN share that they own.
This offer for NTGN stock values it at $2.18 per share. That’s based on BNTX stock’s closing price of $34.55 on Wednesday. The offer of $2.18 per share for NTGN stock is a roughly 77.24% premium over its closing price of $1.23 on Wednesday.
Ugur Sahin, MD, co-founder and CEO of BioNTech, says this about the deal with Neon Therapeutics.

“This acquisition fits with our strategy to expand our capabilities and build our presence in the U.S. and further strengthens our immunotherapy pipeline. I am particularly excited about the adoptive T cell and neoantigen TCR therapies being developed by Neon, which are complementary to our pipeline and our focus on solid tumors.”

The Neon Therapeutics news release notes that the deal has the full support of the company’s Board of Directors. Approval from shareholders and regulators is still needed. So long as there are no problems here, the deal will close in the second quarter of 2020.
NTGN stock was up 38.21% and BNTX stock was down 6.66% when markets closed on Thursday.



https://investorplace.com/2020/01/neon-therapeutics-news-ntgn-stock-rockets-38-on-biontech-deal/
👍️0
ClayTrader ClayTrader 4 years ago
* * $NTGN Video Chart 01-16-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
bakedog38 bakedog38 4 years ago
Bought a position today w/ NTGN …………………..

Great things in the works 2020 , GLTA !
👍️0
Crazy Money Crazy Money 4 years ago
weeeeeee
👍️0
stock1ace1 stock1ace1 5 years ago
A publication is huge news? Since when ?
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
ack to News Results
Neon Therapeutics Shares Rise on Publication in Scientific Journal
6:44 pm ET September 5, 2019 (Dow Jones) Print


By Dave Sebastian

Shares of Neon Therapeutics Inc. (NTGN) rose more than 14% in after-hours trading Thursday after the company published a paper in a scientific journal that details a process for predicting MHC class II cancer-specific neoantigens.
The paper, titled "Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction," was published in the scientific journal Immunity.
The company said predicting cancer-specific antigens is a precursor to developing immunotherapies that could destroy malignant cells.
Neon said it will integrate the MHC class II prediction tool into its RECON bioinformatics platform, which identifies and predicts neoantigen targets associated with a patient's tumor.

Write to Dave Sebastian at dave.sebastian@wsj.com
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
NTGN~3.60 ah close ,,~CRAZYYY GOOOO,LOAD UP FAST IN AM,chart will EXPLODE CRAZYYY,could see 6-8 dollars pps https://www.stockscores.com/charts/charts/?ticker=ntgn
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
NTGH~~HUGE NEWS~~Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens
Print
Alert
Neon Therapeutics (NASDAQ:NTGN)
Intraday Stock Chart
Today : Thursday 5 September 2019

Click Here for more Neon Therapeutics Charts.
Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced publication in the scientific journal Immunity of a breakthrough process for predicting which neoantigens will be presented by MHC class II molecules in the tumor microenvironment. Predicting the relevant cancer-specific antigens is a crucial precursor to developing immunotherapies that effectively train T cells to traffic to the tumor and destroy malignant cells. In the paper, titled “Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction,” Neon’s proprietary mono-allelic profiling technology called MAPTAC™ facilitated the development of convolutional neural network-based predictors. These algorithms achieved up to a 61-fold improvement in predicting MHC class II peptides compared to publicly available tools. This MHC class II technology will be integrated into Neon’s RECON bioinformatics platform and is expected to improve the efficacy of immunotherapies developed by Neon by predicting recruitment of CD4+ T cells, which are believed to be important in controlling tumor growth.
“The publication of this work represents an extensive research initiative to significantly improve the recruitment of CD4+ T cell responses. We believe this novel technology and prediction approach significantly advances the neoantigen field by setting a new benchmark for understanding the MHC class II pathway. These new insights may enable the development of improved immunotherapies, as well as therapies for other areas, including autoimmune disorders,” said Richard Gaynor, M.D., Neon’s President of Research and Development.

Neon will be integrating its MHC class II prediction tool into its RECON bioinformatics platform, which is powered by machine-learning neural networks and trained on proprietary MAPTAC data sets. RECON identifies, predicts and selects the most therapeutically relevant neoantigen targets associated with each patient’s tumor. This information is used to design personal immunotherapies customized to each patient’s unique mutational fingerprint and precision immunotherapies targeting shared cancer neoantigens.

“Until recently, neoantigen-directed therapies have been focused primarily on eliciting CD8+ T cell responses toward ligands presented on MHC class I molecules. It has been historically difficult to predict the antigens that will be presented through class II due to inaccurate peptide binding prediction and unsolved complexities of the class II pathway. Through the research published today in Immunity, we have integrated novel proteomics and genomics strategies to build a more accurate tool for defining and understanding the rules of the class II pathway, leading to algorithms that have been shown to significantly outperform currently available prediction tools,” said Jennifer Abelin, Ph.D., Associate Director, Proteomics at Neon and lead author of the paper.

The findings in the Immunity publication demonstrate that Neon’s proprietary class II prediction algorithms substantially outperform NetMHCIIpan, the current benchmark for class II prediction. Key findings in the research include the development of novel proteomic strategies that resolve over 40 MHC class II motifs and the observation that intra-tumoral MHC class II presentation is dominated by professional antigen presenting cells (APCs) rather than tumor cells. Tracking which tumor epitopes are most readily phagocytosed and presented by APCs further enhances the ability to pinpoint therapeutically relevant epitopes.

A proprietary approach powering Neon’s RECON bioinformatics platform for MHC class I molecules was first described in an earlier article published in Immunity in 2017.

About Neon Therapeutics
Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both vaccine and T cell therapies, including NEO-PV-01, a clinical-stage neoantigen vaccine for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a subset of hormone receptor-positive (HR+) breast cancer.

For more information, please visit neontherapeutics.com.

Forward-Looking Statements
This press release contains “forward-looking statements” of Neon Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding the design and potential efficacy of our therapeutic approaches; the design and efficacy of our proprietary bioinformatics platform, and our ability to improve immunotherapies. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing and conduct of studies and other development requirements for our product candidates; the risks related to the development. enhancement and effectiveness of our proprietary bioinformatics platform and the ability of that platform to accurately identify, predict and select the most therapeutically relevant neoantigens; the risk that any one or more of our product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future studies or trials; risks related to our ability to protect and maintain our intellectual property position; and risks related to the ability of our licensors to protect and maintain their intellectual property position. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Neon’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Neon’s most recent Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Neon’s other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Neon undertakes no duty to update this information unless required by law.

Investor Contact:
Paul Cox, Corporate Affairs and Strategy
pcox@neontherapeutics.com
617-337-4762

Media Contact:
Stephanie Simon, Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333

👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
The findings in the Immunity publication demonstrate that Neon’s proprietary class II prediction algorithms substantially outperform NetMHCIIpan, the current benchmark for class II prediction. Key findings in the research include the development of novel proteomic strategies that resolve over 40 MHC class II motifs and the observation that intra-tumoral MHC class II presentation is dominated by professional antigen presenting cells (APCs) rather than tumor cells. Tracking which tumor epitopes are most readily phagocytosed and presented by APCs further enhances the ability to pinpoint therapeutically relevant epitopes.

A proprietary approach powering Neon’s RECON bioinformatics platform for MHC class I molecules was first described in an earlier article published in Immunity in 2017.
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
NTGH~~gonna run in PM am,buy some
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
NTGN AH huge news,3.48 now
👍️0
jondoeuk jondoeuk 5 years ago
This might be useful In https://t.co/T8Ig1fRJrW, Keskin et al. designed a neoantigen vacc trial for pts with newly dx'd MGMT-unmethylated glioblastoma: 1) surgical resection, 2) radiotherapy (RT), 3) personalized neoantigen vacc (prepared using WES and RNA-seq, HLA-typing, and #NetMHCpan). /1— Nils-Petter Rudqvist (@NP_Rudqvist) January 7, 2019
👍️0
jondoeuk jondoeuk 5 years ago
New data from a PhIb trial in pts with ndGBM https://www.nature.com/articles/s41586-018-0792-9

Other trials are ongoing https://clinicaltrials.gov/ct2/show/NCT03422094 https://clinicaltrials.gov/ct2/show/NCT03223103
👍️0

Your Recent History

Delayed Upgrade Clock